Ad-RTS-hIL-12
- Generic Name
- Ad-RTS-hIL-12
- Drug Type
- Biotech
Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma
Phase 2
Terminated
- Conditions
- Glioblastoma
- Interventions
- First Posted Date
- 2019-07-02
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Alaunos Therapeutics
- Target Recruit Count
- 40
- Registration Number
- NCT04006119
- Locations
- 🇺🇸
Cedars Sinai, Los Angeles, California, United States
🇺🇸Baptist MD Anderson Cancer Center, Jacksonville, Florida, United States
🇺🇸University of California - San Francisco, San Francisco, California, United States
A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma
Phase 1
Completed
- Conditions
- Glioblastoma MultiformeAnaplastic Oligoastrocytoma
- Interventions
- First Posted Date
- 2014-01-01
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Alaunos Therapeutics
- Target Recruit Count
- 40
- Registration Number
- NCT02026271
- Locations
- 🇺🇸
Cedars-Sinai, Los Angeles, California, United States
🇺🇸University of California - San Francisco, San Francisco, California, United States
🇺🇸Northwestern, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath